Mark Emberton, MD

Profesor Urology and currently serves Dean of Medicine at University College London.

A pioneer of Focal Therapy of Prostate Cancer using High Frequency Ultrasound (HIFU) waves and introduced cognitive fusion for Biopsy and Treatment of Prostate Cancer with emphasis in Quality of life measures.

He has served as Director of the Division of Surgery and Interventional Science  He is also UCL Partners' Pathway Director for urological oncology for London Cancer - a provider network serving 4 million people that live north of the river Thames in London. He is the Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. As Professor of Interventional Oncology at UCL he leads a clinical innovation team that majors in experimental medicine by combining bio-engineering and nanotechnology with early phase trials in men with prostate cancer.

His work encompasses the areas of diagnosis, risk stratification and therapy. He is also interested in the methodological aspects of clinical research, particularly on the use of alternatives to the randomised control trial in surgery and design aspects of diagnostic studies. He is involved in guideline production and appraisal and is interested in the formulation of evidence based management policies.

He is an active researcher, lectures widely and has published over 200 peer reviewed articles in numerous scientific journals. Mark Emberton is a founding Partner of London Urology Associates. He is a Trustee of the charity, Prostate Action